RxDoctor Payments DataLook up a doctor →

Manjot Gill, MD

Ophthalmology · Chicago, ILNPI 1396776894

Payments from drug & device makers

$1,409,509in general payments, 2019–2025

Across 178 payments — averaging $7918.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.4M
  • Genentech USA, Inc.$37K
  • Regeneron$12K
  • Hoffmann-la Roche Limited$7K
  • Dutch Ophthalmic, USA$840
  • Glaukos Corporation$203
  • plus $452 from 5 others
$16,486in research payments, 2019–2025

Across 15 payments — averaging $1099.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$10K
  • Regeneron$7K

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,409,509 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,868,368
Medicare patients
720
Services billed
22,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →